Soleno Therapeutics Engages Investors at February Conferences
Soleno Therapeutics, Inc. (NASDAQ: SLNO), a dynamic player in the biopharmaceutical field, is set to make impactful appearances at a series of investor conferences coming up in February. Based in Redwood City, California, this clinical-stage company is renowned for its commitment to developing innovative treatments targeting rare diseases.
Highlighting Key Events This February
The first notable event is the Guggenheim SMID Cap Biotech Conference, with the company scheduled for a fireside chat on a Thursday. Investors can tune in at 2:00 PM ET to get insights into Soleno's advancements and strategic initiatives.
Details for the Guggenheim Conference
This conference is not just an opportunity for presentation; it's a platform for engaged discussions about the company's future. The webcast will provide accessibility, inviting investors and stakeholders to connect deeply with Soleno's mission.
Oppenheimer Annual Healthcare Life Sciences Conference
Following the Guggenheim event, Soleno will also participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference, where a corporate presentation is set for Tuesday at 2:40 PM ET. Here, the spotlight will be on its groundbreaking therapeutic endeavors.
Presentation Insights
This presentation aims to bridge the gap between innovative research and market demand, showcasing Soleno's robust pipeline and its potential impact on the treatment landscape for rare diseases.
Post-Event Availability
Investors interested in the insights shared during these conferences can expect that both events will be available for replay in the Investors section of Soleno's website. This accessibility underscores the company's commitment to transparency and communication in the investor community.
About Soleno Therapeutics, Inc.
At the core of Soleno's operations is the focus on developing pioneering therapeutics aimed at transforming the lives of individuals suffering from rare disorders. The company's lead therapeutic candidate, DCCR (diazoxide choline) extended-release tablets, is currently under FDA review and has received Priority Review status. This innovation is specifically targeting Prader-Willi syndrome, a rare genetic disorder associated with various health challenges.
The Importance of DCCR
DCCR represents hope for families affected by Prader-Willi syndrome, offering a once-daily oral treatment option that has the potential to significantly improve quality of life. With the ongoing review by regulatory authorities, anticipation surrounding this candidate is palpable.
Stay Connected with Soleno
If you're keen on the unfolding journey of Soleno Therapeutics, their website is a valuable resource. Frequent updates and detailed information about their therapeutic developments are prominent, staying in line with their ethos of maintaining an engaged and informed investor base.
Corporate Contact for Investor Relations
For further inquiries, Brian Ritchie from LifeSci Advisors stands as a point of contact. He is available to discuss investment-related questions at 212-915-2578.
Frequently Asked Questions
1. What is the primary focus of Soleno Therapeutics?
Soleno Therapeutics specializes in developing treatments for rare diseases, particularly through innovative therapeutics.
2. What important event is Soleno participating in February?
Soleno will participate in the Guggenheim SMID Cap Biotech Conference and the Oppenheimer Annual Healthcare Life Sciences Conference.
3. What is the significance of DCCR?
DCCR is a lead therapeutic candidate for treating Prader-Willi syndrome and is under review by the FDA with Priority Review status.
4. How can investors access information from the conferences?
Replays of both investor conferences will be available in the Investors section of Soleno's website.
5. Who can investors contact for more information about Soleno?
Brian Ritchie from LifeSci Advisors is available for inquiries at 212-915-2578.
